(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.9%.
Dyne Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast DYN's revenue for 2026 to be $920,446,398, with the lowest DYN revenue forecast at $540,602,212, and the highest DYN revenue forecast at $1,300,290,584. On average, 4 Wall Street analysts forecast DYN's revenue for 2027 to be $15,661,530,609, with the lowest DYN revenue forecast at $3,094,236,345, and the highest DYN revenue forecast at $26,522,229,048.
In 2028, DYN is forecast to generate $58,050,007,788 in revenue, with the lowest revenue forecast at $54,643,502,534 and the highest revenue forecast at $61,456,513,043.